Ignite Creation Date:
2025-12-24 @ 6:56 PM
Ignite Modification Date:
2025-12-27 @ 1:09 PM
Study NCT ID:
NCT01034657
Status:
TERMINATED
Last Update Posted:
2017-08-11
First Post:
2009-12-16
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-11
Start Date Type:
None
Primary Completion Date:
2012-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2012-08
Completion Date Type:
ACTUAL
First Submit Date:
2009-12-16
First Submit QC Date:
None
Study First Post Date:
2009-12-17
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2016-08-25
Results First Submit QC Date:
None
Results First Post Date:
2017-01-25
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-08-08
Last Update Post Date:
2017-08-11
Last Update Post Date Type:
ACTUAL